Note: Please do not reply to this email as replies will not be reviewed. If you have a question or comment, click here.
Current as of Oct. 20, 2020, at 7:00 a.m.
COVID-19 Testing Sites in Florida
  • Drive-Thru Testing sites available are listed by county. Each walk up site can test up to 200 individuals per day. Access the list here.

Safe. Smart. Step-by-Step.

Florida’s Reemployment Assistance Dashboard: View DEO Dashboard Here.

Florida Department of Health COVID Dashboard: Access dashboard here.

Graphs, Charts, and Real-time Tracking of COVID-19

Data Sources

Data Sources on Social Media

Other Resources

Current Statistics

  • Fatality rate in Florida - 2.1%
  • Covid fatality rate in FL by age group:
  • 15-24 years old - .03%
  • 25-34 years old - .07%
  • 35-44 years old - .23%
  • 45-54 years old - .56%
  • 55-64 years old - 1.8%
  • 65-74 years old - 5.9%
  • 75 and up - 18.5%
  • Seasonal influenza mortality rate in the US (2017 CDC) 18-49 yo - .02%

  • Median age of new Covid cases - 38 years old
  • Emergency department visits w/ COVID-like illness - 15% decrease
  • ICU beds available in Florida - 28%
  • Hospital beds available in Florida - 28%

Vaccine Tracking

Last updated: October 16, 2020 10:40 AM PST

213
vaccines are in development.

36
are now in clinical testing.


Pfizer has already made “several hundred thousand doses” of a potential coronavirus vaccine as it prepares to seek emergency use in the US by November.

The drugmaker told the Mail on Sunday that scientists in its main British lab have also unearthed drugs that could provide a potential complete cure for COVID-19, as opposed to merely a preventative vaccine.

The firm’s UK boss, Ben Osborn, said the company is manufacturing the huge stockpile of its current vaccine candidate in Belgium “at risk and at scale,” calling it “tremendously exciting.”

“The hope here is that we essentially come up with a medicine that disrupts the virus and ultimately prevents it worsening the condition of a patient,” he told the Mail’s financial site, This Is Money.

“It was great to see the first vial coming off the manufacturing line. It just brought a tremendous smile to my face to see all of this work actually result in a product,” he said.

But “we can only go as fast as the science allows us to,” he stressed.

Pfizer expects to know whether the vaccine works by the end of this month, but the company still has to prove the shot is safe and can be manufactured properly to seek a so-called emergency use authorization, CEO Albert Bourla said Friday.

If it’s safe, he expects his company to seek emergency use in the US in the third week of November.
“We are operating at the speed of science,” he said.


State public health departments say they’re ready to leap into action as soon as a COVID-19 vaccine is approved but caution so many things are still unknown that exactly what that leap looks like is hard to say right now.

For Dr. Nirav Shah, director of the Maine Center for Disease Control and Prevention, it's like planning an outdoor picnic for 1.3 million of his closest friends (the population of Maine) without knowing how much food he has, who's coming, how he's going to invite them and what they can and can't eat.

"We plan for things we have knowledge around and move forward from there," he said.

The good news is that the earliest date a vaccine is expected to arrive is now around Thanksgiving so that gives states a little breathing room. There had been the possibility that a vaccine could become available as soon as Nov. 1.

To get ready, in Maine the public health department is planning "down to the person,"  Shah said. "We're looking at how many miles our public health nurses may need to drive." 

On Friday state public health departments submitted vaccination distribution plans to the U.S. Centers for Disease Control. The plans were as detailed as they could be given the many things that are still unknown:
  • When a vaccine or vaccines will become available.
  • Which groups will be first in line to get it and who comes next.
  • What kind of storage and refrigerator or freezer requirements they might have. At least one must be stored at -94°.
  • For vaccines that require two doses (all but one), when the second dose must be administered.
  • Information about whether a certain vaccine works or doesn't work in specific populations such as the elderly, pregnant women or the young. 

In a call with reporters Monday, public health officials talked about how they're preparing and what they still need.

This involves hours and hours of meetings: Last week state health officials spent two hours meeting with Pfizer just about the packaging it has developed to keep the vaccine cold as it's distributed and stored, said Claire Hannan, executive director of the Association of Immunization Managers.

Maine's Shah said he's having multiple meetings every day and many at night to get ready for what will be one of the biggest public health pushes of the modern era.

The final plan for who gets COVID-19 vaccine first will come from the CDC's Advisory Committee on Immunization Practices. That committee is standing ready to meet the day or the day after a vaccine is approved, Shah said.

But even without the official plan, state health officials have a pretty good idea of the distribution order based on a report released earlier this month by the National Academies of Sciences, Engineering and Medicine.

The first phase, 1a, is very likely to be front-line health care workers. That will make it relatively easy because those vaccinations will take place at hospitals, which are already set up for doing large-scale vaccination efforts, Shah said.

It's when things get to the early stages of Phase 2, which includes people with preexisting conditions that put them at greater risk for becoming seriously ill or dying of COVID that it gets more complicated.

Maine has an older population and many people with preexisting conditions. "That's a large swath of Maine's population," Shah said.

There's also a complex and delicate computer interface to create. All states have immunization registries to track childhood immunizations. Those are now being expanded to include COVID-19 vaccines.

And states are building systems to remind patients to come back for their second shot, if one is needed, and which of the possible multiple vaccines they received so they know which one to get a second time. 
Also at issue: Maintaining patient privacy at a faster pace than usual – recording vaccinations within 24 hours instead of five days.

"We've been telling our providers they're going to need to be reporting into our system every night," Shah said. The state's pressure-testing its systems to make sure they can handle the influx of information.

In Mississippi, state health officials have been working hard to get ready, said Dr. Thomas Dobbs, the state health officer.

"This is going to be a Herculean effort," he said. 

Retail sales and food-services spending posted a strong gain in September, rising 1.9 percent from the prior month, well above the 0.7 percent consensus expectation. The September gain was the fifth in a row following two devastating declines in March and April and puts the monthly total well above the longer-term trend and at a new record high. Core retail sales, which exclude motor vehicles and gasoline retailers, posted a 1.5 percent gain for the month putting them well above trend and at a record high as well.

From a year ago, total retail sales are up 5.4 percent while core retail sales show a 5.9 percent rise. Both are back to the growth rates achieved just before the outbreak of Covid-19 and implementation of government lockdown policies.

Unit-vehicle sales, reported earlier in the month, have also staged a very solid recovery, with sales of light vehicles totaling 16.3 million at an annual rate in September. For the month, light-truck sales totaled 12.6 million at an annual rate, up 8.2 percent from the 11.6 million-rate in August but well ahead of the 6.7 million-rate in April. Car sales also had a solid gain, rising 5.7 percent to a 3.7 annual rate versus 3.5 in August and 2.0 in April.

Results across the various categories of retailers were mostly positive in September. Just one category, electronics and appliance stores, reported a decline in September sales, falling 1.6 percent for the month. Gainers were led by an 11.0 percent surge for clothing and accessories stores followed by a 5.7 percent gain for sporting goods, hobby, musical instrument, and book stores, and a 3.6 percent increase for motor vehicles and parts retailers.

The run of strong monthly gains recently leaves five of the 13 categories with sales below their pre-lockdown levels. Gasoline stations are 16 percent below January followed by restaurants (15 percent below), clothing and accessory stores (13 percent below), electronics and appliances (6 percent below), and miscellaneous store retailers (1 percent below).

On the upside, nonstore retail sales (up 0.5 percent in September and 23.8 percent from September 2019) are 23 percent above January 2020 levels. Sporting-goods, hobby, musical-instrument, and bookstores saw a 5.7 percent gain in September, and are up 14.4 percent from a year ago and are 15 percent above January 2020.

Retail sales rose to another record high in September as widespread quarantines and lockdowns continue to be eased. Businesses and consumers are coming out of the policy-induced economic coma and while aggregate retail spending is at a new high, results still vary greatly by industry. A full return to pre-pandemic conditions for the overall economy and the labor market is likely many months, and possibly many quarters, away but at least the process is underway.

However, uncertainty about the progression of the virus and government policies is sustaining heightened uncertainty and remains a significant threat to the recovery. The approaching elections also have the potential to be destabilizing.

The registration application for autonomous APRNs is now available. The application can be found in both the MQA online system under “Manage My License” and under the Resources/Nursing Applications tab of the Board website.

Eligibility for registration as an autonomous APRN includes the following:
  • at least 3,000 clinical practice hours under the supervision of an allopathic or osteopathic physician within the past 5 years. These hours may include clinical instructional hours. [See Section 464.0123(1)(c) F.S. for complete requirements];
  • three graduate-level semester hours, or the equivalent, in differential diagnosis and 3 graduate-level semester hours, or the equivalent, in pharmacology completed within the past 5 years (documentation required); and
  • not been subject to disciplinary action as specified in Section 456.072 F.S. or Section 464.018 F.S., or any similar disciplinary action in any state or jurisdiction within the past 5 years.

There is no fee associated with submitting the registration application.